GLP-1 Next Generation 2026-2028: The 5 Molecules to Watch

The incretin class has evolved rapidly from liraglutide and exenatide through semaglutide, dulaglutide, and tirzepatide into a multi-mechanism pipeline that is redefining the efficacy ceiling of pharmacologic metabolic therapy. Between 2026 and 2028 five investigational and recently approved molecules will generate pivotal clinical readouts, regulatory decisions, and market launches that shape the next generation of obesity and metabolic medicine.

This overview catalogs the five molecules most relevant for research, regulatory, and market watchers: orforglipron, retatrutide, survodutide, CagriSema, and oral tirzepatide. Each is evaluated by mechanism, developmental stage, key efficacy data, regulatory timeline, and strategic differentiation. The goal is to provide a research-oriented reference frame rather than treatment guidance.

Orforglipron (Foundayo, Eli Lilly) is a once-daily oral small-molecule GLP-1 receptor agonist, approved by the U.S. Food and Drug Administration in May 2026 based on the ATTAIN-1 Phase 3 trial (NCT05869903). The pivotal data showed a mean body weight reduction of 12.4 percent at 72 weeks on the 36 mg dose versus 0.9 percent on placebo. Unlike oral semaglutide, orforglipron can be taken with or without food or water, removing the fasting protocol barrier.

Strategic significance: first non-peptide oral GLP-1, lower unit production cost than peptide analogs, suitable for markets with cold-chain constraints. Future milestones include the ACHIEVE-1 type 2 diabetes Phase 3 readout, the ATTAIN-CV cardiovascular outcomes trial, and investigational studies in MASH and obstructive sleep apnea.

Retatrutide (LY3437943, Eli Lilly) is a once-weekly injectable synthetic peptide with balanced agonist activity at the GIP, GLP-1, and glucagon receptors. TRIUMPH-4 (NCT05931367) Phase 3 topline data reported in the first quarter of 2026 showed a 28.7 percent mean body weight reduction from baseline at week 88 on the 12 mg dose, the largest weight loss magnitude reported to date in a Phase 3 obesity trial.

Strategic significance: new efficacy ceiling beyond tirzepatide, potential to approach bariatric surgery outcomes, mechanistic interest in glucagon receptor contribution. Remaining steps include TRIUMPH-3 (type 2 diabetes), TRIUMPH-HCM (HFpEF), a MASH trial, and a projected U.S. New Drug Application submission in the second half of 2026 with potential approval in 2027.

Survodutide (BI 456906, Boehringer Ingelheim and Zealand Pharma) is a once-weekly dual glucagon/GLP-1 receptor agonist in Phase 3 development across obesity (SYNCHRONIZE-1, NCT06309992), obesity plus type 2 diabetes (SYNCHRONIZE-2), and MASH (LIVERAGE). Phase 2 data in obesity showed approximately 19 percent mean body weight reduction at 46 weeks on the highest dose, and Phase 2 MASH data showed 64 percent steatohepatitis resolution without worsening fibrosis.

Strategic significance: dual-indication metabolic and liver disease positioning, glucagon-mediated hepatic fat reduction, most advanced Phase 3 dataset for dual GLP-1/glucagon agonism. Readouts expected in 2026 to 2027 and regulatory submissions in the late 2027 to 2028 timeframe.

CagriSema (Novo Nordisk) is a once-weekly fixed-dose subcutaneous combination of cagrilintide, a long-acting amylin receptor agonist, and semaglutide, at 2.4 mg plus 2.4 mg. Phase 3 REDEFINE 1 topline data reported in 2024 showed mean body weight reduction of approximately 20.4 percent at 68 weeks in adults with obesity without type 2 diabetes, meeting the primary endpoint but narrowly missing the superiority threshold that Novo Nordisk had publicly targeted.

Strategic significance: first amylin plus GLP-1 dual-peptide combination, mechanistic differentiation through amylin receptor agonism targeting different satiety pathways. REDEFINE 2 (obesity and type 2 diabetes) and REDEFINE 4 (cardiovascular outcomes) readouts are expected to refine the commercial positioning through 2026 and 2027, followed by potential regulatory submission.

Eli Lilly has a Phase 2 oral tirzepatide formulation in development, seeking to translate the dual GIP/GLP-1 agonist tirzepatide from subcutaneous to oral administration. This represents the most technically ambitious oral peptide program currently disclosed publicly, because tirzepatide is a larger and more complex peptide than semaglutide. Formulation approaches under evaluation include enhanced permeation strategies and alternative delivery platforms.

Strategic significance: potential first oral dual GIP/GLP-1 agonist, extending the Mounjaro and Zepbound franchise into oral delivery, complementing orforglipron as a second Eli Lilly oral metabolic option. Phase 3 initiation is expected in the 2026 to 2027 timeframe depending on Phase 2 dose selection and formulation finalization.

• Orforglipron: non-peptide oral small molecule, GLP-1 only, 12.4 percent weight loss at 72 weeks, FDA approved May 2026.
• Retatrutide: subcutaneous peptide, GIP plus GLP-1 plus glucagon, 28.7 percent weight loss at 88 weeks, NDA submission planned 2H 2026.
• Survodutide: subcutaneous peptide, GLP-1 plus glucagon, ~19 percent Phase 2, MASH dual indication, Phase 3 readouts 2026-2027.
• CagriSema: subcutaneous peptide combination, GLP-1 plus amylin, ~20.4 percent at 68 weeks (REDEFINE 1), additional Phase 3 data pending.
• Oral tirzepatide: oral peptide under formulation development, GIP plus GLP-1, Phase 2 ongoing with Phase 3 expected 2026-2027.

Cross-trial comparisons are informative but not clinically decisive due to differences in trial populations, durations, dose-titration schemes, and endpoint definitions. For regulatory and procurement purposes, head-to-head trials or real-world evidence comparisons will eventually supplement the cross-trial summaries provided above.

The Clarivate Drugs to Watch 2026 report identified the GLP-1 franchise as the single largest category of anticipated near-term commercial impact, projecting retatrutide to reach blockbuster status within two years of launch and orforglipron to materially expand the addressable oral GLP-1 market. Collectively, the five molecules described here are expected to push global annual sales of the incretin class beyond 200 billion USD by 2030, according to independent analyst models.

Supply chain, manufacturing capacity, payer coverage dynamics, and competition with emerging oral small molecules will shape the actual commercial trajectory. From a scientific standpoint, the most important question is whether mechanism diversification (triple agonism, amylin co-agonism, oral delivery) continues to deliver incremental efficacy or begins to show diminishing returns against safety and tolerability constraints.

For the research peptide and scientific audit community, the 2026 to 2028 window provides a unique window to catalog, characterize, and verify the chemical identity, purity, and stability of a rapidly expanding set of investigational peptides and small molecules. Regulatory attention to compounded and unapproved copies of investigational GLP-1 agents is increasing, with FDA enforcement actions targeting misrepresented bases of tirzepatide, semaglutide, and retatrutide already documented.

Laboratory researchers handling any investigational incretin analog should verify certificates of analysis, track lot-specific HPLC purity, mass spectrometry identity confirmation, and endotoxin status, and ensure that all research-use designations comply with applicable regulations. ChemVerify continues to catalog vendor-supplied analytical data for these compounds as public research references, strictly within a research-use-only framework.

• Read more: Orforglipron (Foundayo) FDA Approval → https://www.chemverify.com/learn/orforglipron-foundayo-fda-approval-oral-glp1
• Read more: OASIS 4 Oral Semaglutide 25mg Weight Loss → https://www.chemverify.com/learn/oasis-4-trial-oral-semaglutide-25mg-weight-loss
• Read more: Retatrutide TRIUMPH-4 Phase 3 → https://www.chemverify.com/learn/retatrutide-triumph-4-phase-3-28-percent-weight-loss
• Read more: Survodutide SYNCHRONIZE Phase 3 → https://www.chemverify.com/learn/survodutide-synchronize-phase-3-mash-obesity